LON:ETX e-therapeutics (ETX) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About e-therapeutics Stock (LON:ETX) Get e-therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume2.52 million shsAverage Volume758,869 shsMarket Capitalization£52.59 millionP/E RatioN/ADividend Yield3.35%Price TargetN/AConsensus RatingN/A Company Overview e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom. Read More Receive ETX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for e-therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ETX Stock News Headlines858 Therapeutics Announces FDA Fast Track Designation for PARG Inhibitor ETX-19477 for the Treatment of Patients with BRCA-Mutated, HR+/HER2- Unresectable or Metastatic Breast ...August 19, 2026 | finance.yahoo.come-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra OSOctober 1, 2025 | markets.businessinsider.comYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.November 20 at 1:00 AM | Reagan Gold Group (Ad)e-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 ...July 11, 2025 | morningstar.comMe-therapeutics plc: e-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 with Positive Non-clinical DataJuly 10, 2025 | finanznachrichten.dee-therapeutics plc: e-therapeutics Presents New Data Supporting ETX-312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASHMay 7, 2025 | finanznachrichten.dee-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASHMay 7, 2025 | finance.yahoo.comEnsem Therapeutics Announces U.S. FDA IND Clearance to Initiate Clinical Development of ETX-636April 22, 2025 | tmcnet.comSee More Headlines ETX Stock Analysis - Frequently Asked Questions How were e-therapeutics' earnings last quarter? e-therapeutics plc (LON:ETX) announced its earnings results on Tuesday, March, 17th. The company reported GBX (0.87) earnings per share for the quarter, beating analysts' consensus estimates of GBX (0.90) by GBX 0.03. Industry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolLON:ETX CIKN/A Webwww.etherapeutics.co.uk Phone+44-1993-880000FaxN/AEmployees35Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£10.06 million Net MarginsN/A Pretax MarginN/A Return on Equity-38.75% Return on Assets-29.10% Debt Debt-to-Equity Ratio0.33 Current Ratio22.20 Quick Ratio20.13 Sales & Book Value Annual Sales£295 thousand Price / Sales0.00 Cash FlowN/A Price / Cash Flow5.07 Book ValueGBX 5 per share Price / BookN/AMiscellaneous Outstanding Shares584,330,000Free FloatN/AMarket Cap£52.59 million OptionableNot Optionable Beta0.46 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (LON:ETX) was last updated on 5/8/2024 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding e-therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share e-therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.